Pfizer eyes submission after TTR readout; Alnylam gets bump

Pfizer Inc. (NYSE:PFE) reported detailed data from the Phase III ATTR-ACT trial of tafamidis meglumine in patients with transthyretin (TTR) cardiomyopathy showing that the drug led to a 30% improvement in all-cause mortality. However, investors appeared unimpressed by the data as shares of Pfizer were off $0.82 to $41.58 on Monday.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS), both of which have approved compounds targeting TTR, each gained value Monday after Pfizer reported the data. Alnylam was up $15.72 (16%) to $112.59, while Ionis added $3.90 to $53.70...